Martin Mackay News
Most Popular Martin Mackay Story
UPDATED: AstraZeneca cutting 2,200 R&D jobs, slashing neuroscience in restructuring
Hit with sliding profits, a weak late-stage pipeline and a troubling track record on clinical trials, AstraZeneca ($AZN) has decided to trigger another round of layoffs, with 2,200 R&D staffers Read more...
Latest Headlines
- January 24, 2011
- October 20, 2009
- October 15, 2009
- September 24, 2009
- September 30, 2008
- October 4, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
